GLP-3R prices

FROM PEPTIDES CALCULATOR

About Retatrutide

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide that activates the GIP, GLP-1 and glucagon receptors at the same time. It is a 39-amino-acid analog with two Aib residues, an alpha-methyl-leucine, a C-terminal amide and a C20 fatty diacid attached through a linker to lysine 17, which extends its half-life to roughly a week. In phase 2 it produced a mean weight loss of 24.2% at 48 weeks, and the phase 3 TRIUMPH program has reported 25-28% at 80 weeks; it remains investigational, with no approved label or dosing schedule.

Formula

C221 H342 N46 O68

Molar mass

4,731 g/mol

CAS number

2381089-83-2

Amino acids

39

Research evidence described in the source

Limitations noted in the source

• Phase 2 results do not establish an approved regimen or long-term benefit-risk profile.
• Unregulated products labeled retatrutide cannot be assumed equivalent to trial material.
• A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
• Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.